4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,785.00
arrow_upward
+1.61%(+60.00) 1D
ኖቬም 10, 3:30:00 ከሰዓት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,765
High
JP¥3,790
Low
JP¥3,735
Mkt. cap
176.16 ቢ
Avg. vol.
90.11 ሺ
Volume
88.00 ሺ
Dividend
3.30%
Quarterly dividend
JP¥31
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
14.03
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,765
High
JP¥3,790
Low
JP¥3,735
Mkt. cap
176.16 ቢ
Avg. vol.
90.11 ሺ
Volume
88.00 ሺ
Dividend
3.30%
Quarterly dividend
JP¥31
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
14.03
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
Trefis
·
ከ1 ሰዓት በፊት
S&P 500 Stocks At 52-Week Lows: Monday’s Full List
Investing.com UK
·
ከ55 ደቂቃዎች በፊት
S&P 500 Got Its Bounce - Now Comes The Hard Part
Yahoo Finance
·
ከ10 ሰዓቶች በፊት
The Trade Desk (NASDAQ:TTD) beats expectations in strong Q3 2026, stock jumps 21.8%
WSJ
·
ከ10 ሰዓቶች በፊት
U.S. Stocks Climb as Investors Regain Confidence
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp